% krátkých akcií společnosti Nymox Pharmaceutical Corp

Jaká je hodnota metriky % krátkých akcií společnosti Nymox Pharmaceutical Corp?

Hodnota metriky % krátkých akcií společnosti Nymox Pharmaceutical Corp je 4.08%

Jaká je definice metriky % krátkých akcií?

% krátkých akcií (Short% of float) je počet akcií prodaných na krátko v porovnání se všemi akciemi v oběhu (float) vyjádřený v procentech.

Short percentage of float, or short interest ratio, is calculated by taking the total amount of shares shorted and dividing it by the total amount of shares available for trade. It is an indirect metric of investor sentiment. When short percentage of float is high, above 40%, it implies company investors hope shares will decline in value. The percentage is used by both fundamental and technical traders to identify trends. The short percentage of float can also be calculated for entire exchanges to determine the sentiment of the market as a whole. If it is high of around five or greater for an exchange, this can be taken as a bearish signal, and vice versa.

Čemu se věnuje společnost Nymox Pharmaceutical Corp?

nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.

Firmy s metrikou % krátkých akcií podobnou společnosti Nymox Pharmaceutical Corp